A prospective study sought to determine the antibody response of pneumococcal vaccines in patients with multiple myeloma.
Patients receiving daratumumab demonstrated a statistically significant decline in pain symptoms that was sustained over time.
The rate of infusion reactions was substantially lower in patients receiving SC compared with intravenous daratumumab.
Carfilzomib administered once weekly demonstrated benefit in progress-free survival independent of patient frailty.
[Cancer Management and Research] A review of data from clinical trials on the use of carfilzomib, a second-generation PI, in the treatment of R/R multiple myeloma, as well as ongoing studies and prescribing advice.